Mayinglong Pharmaceutical Group Co Ltd Cash Flow Conversion Efficiency
Mayinglong Pharmaceutical Group Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Mayinglong Pharmaceutical Group Co Ltd (600993) has a cash flow conversion efficiency ratio of 0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥139.20 Million ≈ $20.37 Million USD) by net assets (CN¥4.43 Billion ≈ $648.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Mayinglong Pharmaceutical Group Co Ltd (2003–2025)
Cash flow conversion efficiency of Mayinglong Pharmaceutical Group Co Ltd from 2003 to 2025. This chart illustrates how Mayinglong Pharmaceutical Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 600993 live share price for real-time trading data and today's change.
Mayinglong Pharmaceutical Group Co Ltd Cash Flow Conversion Ratio Explained
Mayinglong Pharmaceutical Group Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Mayinglong Pharmaceutical Group Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mayinglong Pharmaceutical Group Co Ltd ranked by their cash flow conversion efficiency. Also see how much is Mayinglong Pharmaceutical Group Co Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PharmaBlock Sciences Nanjing Inc Class A
SHE:300725
|
0.018x |
|
ManpowerGroup Inc
NYSE:MAN
|
-0.061x |
|
GigaCloud Technology Inc Class A Ordinary Shares
NASDAQ:GCT
|
0.132x |
|
CleanSpark Inc
NASDAQ:CLSK
|
-0.148x |
|
Nantong Haixing Electronics Co Ltd
SHG:603115
|
0.000x |
|
Turpaz Industries Ltd
TA:TRPZ
|
0.033x |
|
Hengdian Entertainment Co Ltd Class A
SHG:603103
|
0.135x |
|
Deepak Fertilizers and Petrochemicals Corporation Limited
NSE:DEEPAKFERT
|
0.066x |
Annual Cash Flow Conversion Efficiency for Mayinglong Pharmaceutical Group Co Ltd (2003–2025)
The table below shows the annual cash flow conversion efficiency of Mayinglong Pharmaceutical Group Co Ltd from 2003 to 2025. Review 600993 free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥4.51 Billion ≈ $660.65 Million |
CN¥600.44 Million ≈ $87.86 Million |
0.133x | +12.29% |
| 2024-12-31 | CN¥4.20 Billion ≈ $614.78 Million |
CN¥497.61 Million ≈ $72.82 Million |
0.118x | -24.12% |
| 2023-12-31 | CN¥3.87 Billion ≈ $566.29 Million |
CN¥604.07 Million ≈ $88.39 Million |
0.156x | +65.24% |
| 2022-12-31 | CN¥3.62 Billion ≈ $529.55 Million |
CN¥341.85 Million ≈ $50.02 Million |
0.094x | -47.57% |
| 2021-12-31 | CN¥3.31 Billion ≈ $484.97 Million |
CN¥597.17 Million ≈ $87.38 Million |
0.180x | +87.62% |
| 2020-12-31 | CN¥2.95 Billion ≈ $431.18 Million |
CN¥282.99 Million ≈ $41.41 Million |
0.096x | -48.52% |
| 2019-12-31 | CN¥2.63 Billion ≈ $385.58 Million |
CN¥491.58 Million ≈ $71.93 Million |
0.187x | +42.35% |
| 2018-12-31 | CN¥2.35 Billion ≈ $344.15 Million |
CN¥308.24 Million ≈ $45.11 Million |
0.131x | -16.43% |
| 2017-12-31 | CN¥2.27 Billion ≈ $332.31 Million |
CN¥356.17 Million ≈ $52.12 Million |
0.157x | +32.02% |
| 2016-12-31 | CN¥2.02 Billion ≈ $295.13 Million |
CN¥239.60 Million ≈ $35.06 Million |
0.119x | +22.57% |
| 2015-12-31 | CN¥1.89 Billion ≈ $276.06 Million |
CN¥182.85 Million ≈ $26.76 Million |
0.097x | +47.44% |
| 2014-12-31 | CN¥1.70 Billion ≈ $248.58 Million |
CN¥111.67 Million ≈ $16.34 Million |
0.066x | -20.76% |
| 2013-12-31 | CN¥1.57 Billion ≈ $229.19 Million |
CN¥129.94 Million ≈ $19.01 Million |
0.083x | -29.74% |
| 2012-12-31 | CN¥1.43 Billion ≈ $209.74 Million |
CN¥169.25 Million ≈ $24.77 Million |
0.118x | +106.81% |
| 2011-12-31 | CN¥1.32 Billion ≈ $193.15 Million |
CN¥75.37 Million ≈ $11.03 Million |
0.057x | +663.58% |
| 2010-12-31 | CN¥1.13 Billion ≈ $164.95 Million |
CN¥-11.42 Million ≈ $-1.67 Million |
-0.010x | -104.93% |
| 2009-12-31 | CN¥1.05 Billion ≈ $153.90 Million |
CN¥216.11 Million ≈ $31.62 Million |
0.205x | +74.55% |
| 2008-12-31 | CN¥871.43 Million ≈ $127.52 Million |
CN¥102.59 Million ≈ $15.01 Million |
0.118x | +1448.66% |
| 2007-12-31 | CN¥853.12 Million ≈ $124.84 Million |
CN¥6.49 Million ≈ $948.97K |
0.008x | -91.36% |
| 2006-12-31 | CN¥855.21 Million ≈ $125.14 Million |
CN¥75.27 Million ≈ $11.01 Million |
0.088x | -10.15% |
| 2005-12-31 | CN¥596.55 Million ≈ $87.29 Million |
CN¥58.43 Million ≈ $8.55 Million |
0.098x | -0.19% |
| 2004-12-31 | CN¥552.20 Million ≈ $80.80 Million |
CN¥54.19 Million ≈ $7.93 Million |
0.098x | -66.37% |
| 2003-12-31 | CN¥231.35 Million ≈ $33.85 Million |
CN¥67.52 Million ≈ $9.88 Million |
0.292x | -- |
About Mayinglong Pharmaceutical Group Co Ltd
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. It operates through three segments: Pharmaceutical Manufacturing; Pharmaceutical Wholesale and Retail; and Medical Services. The company offers functional cosmetics, care products and food, Chinese herbal medicines, and medical devices. It a… Read more